Restoring tumor immunogenicity with dendritic cell reprogramming

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Olga Zimmermannova
  • Alexandra G. Ferreira
  • Ervin Ascic
  • Marta Velasco Santiago
  • Ilia Kurochkin
  • Morten Hansen
  • Inês Caiado
  • Ilja E. Shapiro
  • Justine Michaux
  • Marion Humbert
  • Diego Soto-Cabrera
  • Hreinn Benonisson
  • Rita Silvério-Alves
  • David Gomez-Jimenez
  • Carina Bernardo
  • Monika Bauden
  • Roland Andersson
  • Mattias Höglund
  • Kenichi Miharada
  • Yukio Nakamura
  • Stephanie Hugues
  • Lennart Greiff
  • Malin Lindstedt
  • Fábio F. Rosa
  • Cristiana F. Pires
  • Michal Bassani-Sternberg
  • Carlos Filipe Pereira

Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. We used the minimal gene regulatory network of type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen-presenting cells (tumor-APCs). Enforced expression of the transcription factors PU.1, IRF8, and BATF3 (PIB) was sufficient to induce the cDC1 phenotype in 36 cell lines derived from human and mouse hematological and solid tumors.Within 9 days of reprogramming, tumor-APCs acquired transcriptional and epigenetic programs associated with cDC1 cells. Reprogramming restored the expression of antigen presentation complexes and costimulatory molecules on the surfaces of tumor cells, allowing the presentation of endogenous tumor antigens on MHC-I and facilitating targeted killing by CD8+ T cells. Functionally, tumor-APCs engulfed and processed proteins and dead cells, secreted inflammatory cytokines, and cross-presented antigens to naïve CD8+ T cells. Human primary tumor cells could also be reprogrammed to increase their capability to present antigen and to activate patient-specific tumor-infiltrating lymphocytes. In addition to acquiring improved antigen presentation, tumor-APCs had impaired tumorigenicity in vitro and in vivo. Injection of in vitro generated melanoma-derived tumor-APCs into subcutaneous melanoma tumors delayed tumor growth and increased survival in mice. Antitumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors. Our approach serves as a platform for the development of immunotherapies that endow cancer cells with the capability to process and present endogenous tumor antigens.

OriginalsprogEngelsk
Artikelnummereadd4817
TidsskriftScience immunology
Vol/bind8
Udgave nummer85
Antal sider20
ISSN0065-2776
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Acknowledgments:W ethankthemembersoftheCellReprogramminginHematopoiesisand ImmunityLaboratoryfordiscussionsandS.Pedreirofortechnicalassistance.W ethankthe CenterforTr ansla tionalGenomics,SciLifeLabLundforprovidingsequencingservices,andLund UniversityBioimagingCenterforscanningelectronmicroscopyassistance.W ewouldalsolike tothanktheLundStemCellCenterFA CS facilityforcellsortingassistanceandtheCentrefor ComparativeMedicineforanimalfacilities.W ethankF .Granucci(UniversityofMilanoBicocca, Italy)andR.Marais(CancerResearchManchesterInstitute,UK)forsharingmousecelllinesand J.Bengzon(LundUniversity),F .Aguilo(UmeåUniversity),andG.B.Jönsson(LundUniversity) forprovidinghumancancercelllines.W ethankZ.Kokaia,H.Ahlenius,andE.Quist(Lund University)forpro viding HEFs(ethicalpermit:6.1.8-2887/2017).W ealsothankhealthydonors andtheCenterforClinicalImmunologyandTr ansfusion MedicineatSkåneUniversityHospital forprovidingleukocyteconcentrates(ethicalpermit:2022:11).Funding:Thisprojecthas received funding from the European Research Council (ERC) under the European Union’s Horizon2020researchandinnovationprogram(grantagreementno.866448).Thisprojectwas alsofundedbyCancerfonden(200939PjF),theSwedishResearchCouncil(2020-00615), NovoNordiskFonden(0056527),theMatsPaulssonFoundation,Swelife,andMedtech4Health (2020-04744),Eurostars-2JointProgram(2021-03371),FCT(PTDC/MED-IMU/4520/2020),and PlanodeRecuperaçãoeResiliênciadePortugalpelofundoNextGenera tionEU (C644865576-00000005).TheKnutandAliceW allenberg Foundation,theMedicalFa culty atLundUniversity, andRegionSkåneareacknowledgedforfinancialsupport.O.Z.issupportedbyaCancerfonden postdoctoralfellowship(190008).A.G.F ., I.C.,andR.S.-A.aresupportedbyFCTscholarships (SFRH/BD/133233/2017,PD/BD/146424/2019,andPD/BD/135725/2018).Expensesforsalary andrunningcostsforM.V .S. andI.M.S.inconnectionwithanalysesperformedatCCIT-DKwere coveredbyAsgard.Authorcontributions:O.Z.,A.G.F ., D.S.-C.,andE.A.conducted reprogramming experiments in vitro and analyzed the data. O.Z., A.G.F ., E.A., C.F .P ., and F .F .R. FA CS-purified tumor-APCs.I.K.,O.Z.,andA.G.F .performedRNA-seqandA T A C-seq analysis.O.Z., A.G.F ., E.A.,I.C.,andR.S.-A.performedimmunofluorescence,liveimaging,andW este rnblotting. K.M.andY .N. providedhumancancercelllines.I.E.S.,J.M.,andM.B.-S.performedandanalyzed immunopeptidomicexperiments.M.V .S., M.Hansen,O.Z.,F .F .R., C.F .P ., Ö.M.,andI.M.S.designed andperformedfunctionalexperimentswithhumanprimarymelanomacells.E.A.,D.S.-C.,O.Z., M.Humbert,S.H.,andH.B.designedandperformedinvivoexperiments.M.B.,R.A.,C.B., M.Höglund,D.G.-J.,L.G.,M.L.,Ö.M.,andI.M.S.providedprimaryhumancancersamplesand discussedclinicalapplicability.C.-F .P ., F .F .R., andC.F .P .attractedfunding.O.Z.,A.G.F ., andC.-F .P . conceptualizedthestudyandwrotethemanuscript.Competinginterests:F .F .R., C.F .P ., andC.-F .P .hav eequityinterestandserveinmanagementpositionsatAsgardTherapeuticsAB,which developscancerimmunotherapiesbasedonDCreprogrammingtechnologies.F .F .R., C.F .P ., and C.-F .P .areinventorsonU.S.patent11,345,891,patentapplicationWO2018/185709,andpatent applicationWO2022/243448(togetherwithO.Z.,A.G.F ., andE.A.)heldbyAsgardTherapeutics thatcoverthecellreprogrammingapproachdescribedhere.Dataandmaterialsavailability: ThesequencingdatageneratedinthisstudyareavailablefromGeneExpressionOmnibus (GEO)underaccessioncodesGSE184527(mouseRNA-seq),GSE200146(humanRNA-seq), GSE224941 (human scRNA-seq), and GSE200341 (human A T A C-seq). Published datasets re-analyzedinthisstudyareavailableunderaccessioncodesGSE103618,GSE162650,and GSE94820.W ehav ecreatedawebapplication(cellreprolab.shinyapps.io/tumorAPC_atlas/) wherevisitorscanexploreprocessedRNA-seqandA T A C-seq data.Themassspectrometry proteomicsdatahav ebeendepositedtotheProteomeXchangeConsortiumviathePRIDE partner repository with the dataset identifier PXD039789. Constructs and vectors used for reprogramming are available from Asgard Therapeutics under a material transfer agreement withthecompany.Allotherdataneededtoevaluatetheconclusionsinthepaperarepresentin thepaperortheSupplementaryMaterials.

Publisher Copyright:
© 2023 The Authors.

ID: 370733375